CD5L and prostate carcinoma: Re-analysis of GSE32269 expression data for primary localized prostate cancer versus castration-resistant bone metastatic PCa (n = 55) confirmed that compared to the downregulated expression of AIM/CD5L transcripts in localized PCa and castration-resistant bone metastatic PCa, regardless of TMPRSS2-ERG fusion status, upregulation of PSA/KLK3 expression was observed in both localized and castration-resistant bone metastatic PCa; Interestingly, in the normal samples, while PSA/KLK3 expression was suppressed, the expression of AIM/CD5L was significantly enhanced (Figure 5C).